Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

43.75USD
9:02pm BST
Change (% chg)

$0.49 (+1.13%)
Prev Close
$43.26
Open
$43.39
Day's High
$43.88
Day's Low
$43.36
Volume
5,554,632
Avg. Vol
6,211,330
52-wk High
$43.88
52-wk Low
$33.20

Select another date:

Mon, Aug 27 2018

Photo

Pfizer rare heart disease drug reduces risk of death by 30 percent in study

NEW YORK Pfizer Inc said on Monday that its drug tafamidis reduced the risk of death for patients with a rare and fatal heart disease by around 30 percent, boosting the prospects of what could be a billion-dollar-a-year drug.

Pfizer rare heart disease drug reduces risk of death by 30 pct in study

NEW YORK, Aug 27 Pfizer Inc said on Monday that its drug tafamidis reduced the risk of death for patients with a rare and fatal heart disease by around 30 percent, boosting the prospects of what could be a billion-dollar-a-year drug.

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Aug 22 Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

Exact Sciences surges after marketing deal with Pfizer for cancer test

Exact Sciences Corp's shares shot up as much as 26 percent on Wednesday after the company said Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer.

UPDATE 1-Exact Sciences surges after marketing deal with Pfizer for cancer test

Aug 22 Exact Sciences Corp's shares shot up as much as 26 percent on Wednesday after the company said Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer.

Exact Sciences signs marketing deal with Pfizer for cancer test

Aug 22 Exact Sciences Corp said on Wednesday Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer, in a bid to boost sales of the product.

Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance

FRANKFURT Pfizer has agreed to pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach.

Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance

FRANKFURT Pfizer has agreed to pay German biotech firm BioNTech up to $425 million (£334.33 million) in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach.

Select another date: